Kelly Lawrence W & Associates Inc. CA reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,085 shares of the company’s stock after selling 1,790 shares during the quarter. Johnson & Johnson comprises approximately 3.5% of Kelly Lawrence W & Associates Inc. CA’s holdings, making the stock its 4th largest position. Kelly Lawrence W & Associates Inc. CA’s holdings in Johnson & Johnson were worth $17,474,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Summit Financial Group Inc. purchased a new stake in Johnson & Johnson during the 2nd quarter valued at $7,221,000. Shine Investment Advisory Services Inc. purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth $177,000. Legacy Capital Partners Inc. increased its stake in shares of Johnson & Johnson by 0.5% in the 2nd quarter. Legacy Capital Partners Inc. now owns 42,227 shares of the company’s stock worth $5,586,000 after purchasing an additional 197 shares in the last quarter. Pioneer Investment Management Inc. increased its stake in shares of Johnson & Johnson by 2.7% in the 2nd quarter. Pioneer Investment Management Inc. now owns 2,269,192 shares of the company’s stock worth $300,192,000 after purchasing an additional 58,785 shares in the last quarter. Finally, HL Financial Services LLC increased its stake in shares of Johnson & Johnson by 0.7% in the 2nd quarter. HL Financial Services LLC now owns 1,575,527 shares of the company’s stock worth $208,427,000 after purchasing an additional 11,100 shares in the last quarter. 65.90% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (NYSE JNJ) traded up $0.66 on Tuesday, reaching $139.67. 6,745,134 shares of the company’s stock traded hands, compared to its average volume of 5,877,685. The firm has a market capitalization of $375,900.00, a P/E ratio of 19.60, a price-to-earnings-growth ratio of 2.85 and a beta of 0.80. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the previous year, the firm posted $1.68 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.41%. Johnson & Johnson’s payout ratio is 58.33%.
JNJ has been the subject of several analyst reports. J P Morgan Chase & Co upped their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Jefferies Group set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Tuesday, August 15th. Cowen set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, August 24th. UBS reissued an “underweight” rating on shares of Johnson & Johnson in a report on Thursday, August 24th. Finally, BMO Capital Markets reissued a “buy” rating and set a $145.00 price objective on shares of Johnson & Johnson in a report on Friday, September 1st. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $144.59.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/05/johnson-johnson-jnj-is-kelly-lawrence-w-associates-inc-cas-4th-largest-position.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.